M. Bocchino (Naples, Italy), K.F. Chung (London, United Kingdom), P. Paredi (London, United Kingdom), L. Uller (Lund, Sweden)
Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS)
R. Di Giovanni, P. D'Andrea, H. Hu, P. Goyal (Basel, Switzerland; East Hanover, United States Of America)
|   |
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
R. M. Mróz, M. P. Ausin, R. Lamarca, E. Garcia Gil (Bialystok, Poland; Barcelona, Spain)
| |
Analysis of comorbidities and treatment patterns by GOLD 2013 criteria: Pooled data from Phase III aclidinium bromide studies
D. Price, M. Thomas, R. Lamarca, E. Garcia Gil (Aberdeen, Southampton, United Kingdom; Barcelona, Spain)
| |
Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis
K. R. Chapman, E. Beck, D. Alcaide, E. Garcia Gil (Toronto, Canada; Rüdersdorf, Germany; Barcelona, Spain)
| |
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
E. Huisman, S. Cockle, Y. Punekar (Houten, Netherlands; Uxbridge, United Kingdom)
| |
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects
A. Allen, A. Henderson, A. Gupta, J. Renaux, N. Brealey (Stevenage, Uxbridge, United Kingdom; Bangalore, India)
| |
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Y. Setoguchi (6-7-1 Nishi-Shinjuku, Shinjyuku-ku, Tokyo, Japan)
| |
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
K. Fujimoto, H. Yamazaki, M. Ura, Y. Kitaguchi (Matsumoto, Japan)
| |
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
J. A. Wedzicha, M. Decramer, P. Olsson, H. Chen, R. Fogel, D. Banerji (London, United Kingdom; Leuven, Belgium; Basel, Switzerland; East Hanover, United States Of America)
| |
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
C. Gessner, S. Korn, W. Schürmann, K. Förster, C. Sieder, S. Hiltl, R. Buhl (Leipzig, Mainz, Marburg, Berlin, Nürnberg, Germany)
| |
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
E. Crisafulli, A. Huerta, M. Guerrero, A. Gimeno, R. Martinez, N. Soler, L. Fernández, R. Menéndez, A. Torres (Mantova, Italy; Barcelona, Valencia, Spain)
| |
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
P. Paggiaro, M. Corradi, H. Raptis, R. Baronio, C. Gessner, Z. Siergiejko, M. Scuri, S. Petruzzelli (Pisa, Parma, Italy; Leipzig, Germany; Bialystok, Poland)
| |
Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
J. Beier, R. Fuhr, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Berlin, Germany; Barcelona, Spain)
| |
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects
S. Vaidya, S. Khindri, N. Calder, S. Machineni, S. Febbraro, R. Fuhr, R. Woessner (Cambridge, United States Of America; Horsham, Merthyr Tydfil, United Kingdom; Hyderabad, India; Berlin, Germany; Basel, Switzerland)
| |
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
J. Beier, M. Hosoe, A. M. Tanase, Y. Takahashi, N. Kataoka, B. Hederer (Wiesbaden, Germany; Basel, Switzerland; Tokyo, Japan)
| |
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
D. Dusser, R. Buhl, M. Castro, H. Kerstjens, P. Paggiaro, M. Engel, P. Moroni-Zentgraf, A. Unseld, E. Bateman (Paris, France; Mainz, Ingelheim am Rhein, Biberach an der Riss, Germany; St. Louis, United States Of America; Groningen, Netherlands; Pisa, Italy; Cape Town, South Africa)
| |
Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients
K. Jarmakowska, P. Kuna (Lodz, Poland)
| |
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
D. Singh, B. Leaker, M. Boyce, M. A. Nandeuil, S. Collarini, F. Mariotti, D. Santoro, P. J. Barnes (Wythenshawe, London, United Kingdom; Courbevoie, France; Parma, Italy)
| |
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
P. C. Chou, C. H. Wang, H. P. Kuo (Taipei, Taiwan)
| |